



Press release

LEUKOCARE and Sanofi Pasteur sign cooperation agreement for vaccine stabilization

Munich, Germany, 25.07.2011

LEUKOCARE AG, a privately-owned specialist company for protein stabilization and biological surface coating today announced the signing of a cooperation agreement with Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY). As part of this cooperation, Sanofi Pasteur will explore LEUKOCARE's SPS platform technology to enhance the shelf-life of selected vaccine formulations.

LEUKOCARE's Stabilizing and Protecting Solutions (SPS) are employed in the biopharmaceutical, medical device and diagnostics industries to enhance the shelf-life of proteins and to enable terminal sterilization by irradiation or Ethylene Oxide. Terminal sterilization allows for a significant reduction in production costs by avoiding complex aseptic production and at the same time, improves product safety, as most sources of error can be excluded in one single step.

About LEUKOCARE

LEUKOCARE is a leading provider of technologies for biological functionalization of surfaces and for stabilizing proteins to extend shelf-life and to enable terminal sterilization by irradiation or gas. As a product-focused, clinical-stage biotechnology company, LEUKOCARE uses its proprietary stabilizing postcoating technology to couple, protect and elute biofunctional molecules. LEUKOCARE can functionalize a wide variety of surfaces including implant surfaces, wound dressings, patches, stents, catheters, columns for ex-vivo blood treatment and others. LEUKOCARE leverages its comprehensive expertise in product-focused industry partnerships. The company offers its know-how in biofunctional coatings, formulation of biologics, and product development to interested parties ranging from service-based collaborations to co-development partnerships.

LEUKOCARE was founded in 2003 and is headquartered in Martinsried near Munich, Germany.

For further information, please visit www.LEUKOCARE.com.

Notes for editors:

Many biologics are prone to chemical and physical degradation as well as destabilization or unfolding in response to temperature, radiation, and hydrolysis during production, sterilization and storage. Thus, shelf life and sterilization are key bottlenecks in the design strategies and market success of new products. LEUKOCARE's Stabilizing and Protecting Solutions (SPS) combine the stabilizing and protecting properties required for shelf-life extension and radiation protection in one single product.

Dr. Wolfram Altenhofen

VP Business Development

Phone: +49 (0)89 780 16 65 – 14

Fax: +49 (0)89 780 16 65 – 11

Email: wolfram.altenhofen@leukocare.com